Zacks.com on MSN2d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...
A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...
Gilead Sciences has entered a strategic partnership with Terray for the discovery and development of small-molecule therapies.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
5d
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued ...
Hyperfine, Inc. , the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system?the Swoop® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback